Skip to main
IDYA

IDYA Stock Forecast & Price Target

IDYA Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 57%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

IDEAYA Biosciences is positioned for success in the precision medicine oncology market due to its focus on integrating small molecule drug discovery with translational biomarker identification. With strong, consistent data from its clinical trials, including a statistically significant improvement in PFS and ORR, and demonstrated potential for real-world use, the company is likely to see accelerated approval for its lead program, darovasertib, in treating metastatic uveal melanoma. Additionally, the company has a strong pipeline of other development candidates and promising preclinical programs, further supporting its long-term growth potential. Investors should consider IDYA as a high-growth, developmental-stage biotech company, with a projected 10-year peak sales of $770M, and an estimated valuation of $58/share.

Bears say

IDEAYA Biosciences is an oncology-focused precision medicine company that faces challenges with the limited market opportunities in neo-adjuvant UM, and uncertainties around the commercialization of their pipeline programs. Key data metrics for IDYA's darovasertib are its 95% PoS for 1L metastatic UM and mPFS of 6.9 months, which, coupled with an early OS trend and favorable ORR and mDoR, drive our positive sentiment; however, we maintain a cautious outlook due to potential risks including disappointing PFS readouts, and limited market opportunity for HLA-A*02:01-negative mUM.

IDYA has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 57% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ideaya Biosciences Inc (IDYA) Forecast

Analysts have given IDYA a Buy based on their latest research and market trends.

According to 14 analysts, IDYA has a Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ideaya Biosciences Inc (IDYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.